Cell And Gene Therapy Manufacturing

  1. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  2. BPI Interviews Purification And Pharma Analytics Leader 6/9/2025

    Jean Luo, VP of Purification and Pharma Analytics, discusses innovations in bioprocessing, including the development of dPCR assays, lentiviral titer systems, chromatography resins, and supply chain.

  3. Optimize Cell Isolation And Activation For Flexibility And Scalability 11/13/2023

    Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step using an active release mechanism for clinical trial or commercial manufacturing.

  4. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  5. Thermo Fisher Scientific Bio-Expo Live 2024: Downstream Bioprocessing 8/15/2024

    Review downstream process tools from Thermo Fisher Scientific to enable optimal biologics purification, including chromatography resins, chemicals, process liquids, and buffers.

  6. Scalable By Design: Streamlining Cell Culture Media Manufacturing 8/15/2024

    Learn ways to help improve quality, simplify technology transfer of proprietary media formulations, and mitigate logistical challenges associated with custom media scale-up processes.

  7. Planning for Success: Supply Resiliency Strategies for Bench to Production 10/18/2023

    Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.

  8. Dr. Peter Marks on the Adoption of Novel Precision Analytics 1/30/2024

    Hear advice for developers who are worried that the FDA will not accept changes in their process that include a new analytical method.

  9. Market Demand For AAV Vectors 11/13/2023

    Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.

  10. How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks 1/30/2024

    In this segment of Cell & Gene Live, Dr. Peter Marks shared what he and his team have learned from current gene therapy approvals to accelerate future approvals.